A phase II trial of panobinostat, an orally available deacetylase inhibitor (DACi), in patients with primary myelofibrosis (PMF), post essential thrombocythemia (ET), and post polycythemia vera (PV) myelofibrosis - DeAngelo, D J; Tefferi, A; Fiskus, W (2010)
(ASH Annual Meeting Abstracts)